Immunotherapy
910 articles
Surprising Clinical Trial Results in Pancreatic and Rectal Cancer
Let’s Win Scientific Advisory Board Chair Dr. Allyson Ocean explains the surprising clinical trial results in pancreatic and rectal cancers.
Large Phase III Global Trial Targets Cancer Metabolism
Dr. Philip Philip focuses on disrupting cancer cell metabolism with devimistat, now in a phase III global clinical trial.
NALIRIFOX Shows Promise in Early Studies
Dr. Zev Wainberg describes the new combination NALIRIFOX, being tested in the NAPOLI-3 clinical trial for advanced pancreatic cancer patients.
Research Highlights from ASCO GI 2026
The latest research on drugs targeting KRAS and new immuotherapy combinations were among the highlights of ASCO GI 2026.
Pancreatic Cancer Research Builds Upon Strengths
The September 2023 AACR Special Conference on Pancreatic Cancer focused on the latest research in KRAS, chemotherapy, and cachexia, among other topics.
MRI-Guided Radiation: A New Option for Pancreatic Cancer Treatment
Dr. Parag Parikh and others are using MRI-guided radiation to provide precision radiation treatment for pancreatic cancer.
Immunology Researchers Solve a Mystery of Metastasis
Physician and researcher Douglas Fearon and his lab have a possible explanation for how cancer cells metastasize, and the role surgery may play in this process.
Precision Promise Places Patients at Center of Research
Dr. Diane Simeone explains the different approach to pancreatic cancer clinical trials taken by the Precision Promise program.
Testing an Experimental Combination of Drugs
A clinical trial for some cancers including pancreatic cancer tests the effectiveness of a checkpoint inhibitor and an antisense oligonucleotide inhibitor.
ASCO GI Symposium Features a Broad Range of Pancreatic Cancer Research
Researchers at ASCO GI 2024 reported on research in health disparities, KRAS and other genetic mutations, and novel treatments.
NAPOLI-3 Trial Meets Primary Endpoint in Metastatic Disease
Dr. Tanios Bekaii-Saab explains the early positive results from the NAPOLI-3 clinical trial, testing the NALIRIFOX combination.
Looking Back at the Year in Research: 2019
Research highlights of 2019 include: approval of a PARP inhibitor, artificial intelligence to diagnose pancreatic cysts, and updated radiation guidelines.
Can a Pancreatic Cancer Screening Test Become a Reality?
Dr. Felice Schnoll-Sussman discusses screening options for pancreatic cancer and criteria for people who might want to get screened.
Cracking the KRAS Code
Dr. Despina Siolas is focusing her research on new treatments for pancreatic cancer, particularly ones that go after KRAS mutations.
Stand Up, Speak Out
Dr. Elizabeth Jaffee outlines all the ways YOU can stand up for research and speak out to make sure funding for science is not cut further.